EP Patent

EP4245299A3 — Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate

Assigned to AstraZeneca AB · Expires 2023-12-13 · 2y expired

What this patent protects

Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include dapagliflozin propylene glycol hydrate is: Formula (Ia) or Formula (Ib) and a pharmaceutical acceptable carrier therefore, which formulation is designed for immedi…

USPTO Abstract

Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include dapagliflozin propylene glycol hydrate is: Formula (Ia) or Formula (Ib) and a pharmaceutical acceptable carrier therefore, which formulation is designed for immediate release. The formulations are used for the treatment of diabetes and related diseases.

Drugs covered by this patent

Patent Metadata

Patent number
EP4245299A3
Jurisdiction
EP
Classification
—
Expires
2023-12-13
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.